发明名称 MUTANTS OF ENDOSTATIN, EM 1 HAVING ANTI-ANGIOGENIC ACTIVITY AND METHODS OF USE THEREOF
摘要 Described herein are novel mutants of endostatin, one of which, designated "EM 1", has anti-angiogenic activity similar or superior to that of wild type endostatin. The invention relates to the discovery of an isolated anti-angiogenic peptide, wherein the C-terminal end of the peptide comprises the amino acid sequence SYIVLCIE, which has anti-angiogenic properties. Designated "EM 1", this protein comprises a mutated endostatin protein, where the mutation comprises a deletion of nine consecutive amino acids from the C-terminus of the mutated endostatin protein (e.g., NSFMTSFSK). EM 1 terminates in the amino acid sequence SYIVLCIE. The invention also comprises isolated polynucleotides encoding EM 1, operably linked to expression sequence, and host cells transformed with such a construct. Antibodies to EM 1 are also disclosed. The invention also relates to processes for producing EM 1, fusion proteins containing EM 1, and compositions comprising EM 1 or fusion products thereof. The invention also discloses methods of producing polypeptides encoding EM 1.
申请公布号 WO9929855(A1) 申请公布日期 1999.06.17
申请号 WO1998US26057 申请日期 1998.12.08
申请人 BETH ISRAEL DEACONESS MEDICAL CENTER;SUKHATME, VIKAS, P. 发明人 SUKHATME, VIKAS, P.
分类号 C12N15/09;A61K31/711;A61K35/12;A61K35/26;A61K35/28;A61K35/34;A61K35/407;A61K38/00;A61K38/48;A61K48/00;A61P1/04;A61P3/04;A61P9/00;A61P9/10;A61P15/18;A61P17/02;A61P17/06;A61P19/02;A61P27/02;A61P29/00;A61P35/00;A61P43/00;C07K14/78;C07K16/18;C07K16/40;C07K19/00;C12N1/15;C12N1/19;C12N1/21;C12N5/10;C12N9/68;C12N15/12;C12P21/02;C12P21/08;C12Q1/68;C12R1/645;(IPC1-7):C12N15/12;C12N15/62;A61K38/39 主分类号 C12N15/09
代理机构 代理人
主权项
地址